|
Hauck, W W; Hyslop, T; Anderson, S (2000) Generalized treatment effects for clinical trials. Stat Med 19:887-99
|
|
Hauck, W W; Tozer, T N; Anderson, S et al. (1998) Considerations in the attainment of steady state: aggregate vs. individual assessment. Pharm Res 15:1796-8
|
|
Hauck, W W; Anderson, S; Marcus, S M (1998) Should we adjust for covariates in nonlinear regression analyses of randomized trials? Control Clin Trials 19:249-56
|
|
Hauck, W W; Hauschke, D; Diletti, E et al. (1997) Choice of student's t- or Wilcoxon-based confidence intervals for assessment of average bioequivalence. J Biopharm Stat 7:179-89
|
|
Hauck, W W; Preston, P E; Bois, F Y (1997) A group sequential approach to crossover trials for average bioequivalence. J Biopharm Stat 7:87-96
|
|
Hauck, W W; Bois, F Y; Hyslop, T et al. (1997) A parametric approach to population bioequivalence. Stat Med 16:441-54
|
|
Anderson, S; Hauck, W W (1996) The transitivity of bioequivalence testing: potential for drift. Int J Clin Pharmacol Ther 34:369-74
|
|
Hauck, W W; Anderson, S (1994) Measuring switchability and prescribability: when is average bioequivalence sufficient? J Pharmacokinet Biopharm 22:551-64
|
